210 related articles for article (PubMed ID: 35054996)
21. Potent antimyeloma activity of a novel ERK5/CDK inhibitor.
Álvarez-Fernández S; Ortiz-Ruiz MJ; Parrott T; Zaknoen S; Ocio EM; San Miguel J; Burrows FJ; Esparís-Ogando A; Pandiella A
Clin Cancer Res; 2013 May; 19(10):2677-87. PubMed ID: 23532886
[TBL] [Abstract][Full Text] [Related]
22. A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022).
Kovalová M; Baraka JP; Mik V; Jorda R; Luo L; Shao H; Kryštof V
Expert Opin Ther Pat; 2023 Feb; 33(2):67-87. PubMed ID: 36975020
[TBL] [Abstract][Full Text] [Related]
23. Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors.
Kalan S; Amat R; Schachter MM; Kwiatkowski N; Abraham BJ; Liang Y; Zhang T; Olson CM; Larochelle S; Young RA; Gray NS; Fisher RP
Cell Rep; 2017 Oct; 21(2):467-481. PubMed ID: 29020632
[TBL] [Abstract][Full Text] [Related]
24. A Cdk7-Cdk4 T-loop phosphorylation cascade promotes G1 progression.
Schachter MM; Merrick KA; Larochelle S; Hirschi A; Zhang C; Shokat KM; Rubin SM; Fisher RP
Mol Cell; 2013 Apr; 50(2):250-60. PubMed ID: 23622515
[TBL] [Abstract][Full Text] [Related]
25. Is Cdk7/cyclin H/MAT1 the genuine cdk activating kinase in cycling Xenopus egg extracts?
Fesquet D; Morin N; Doree M; Devault A
Oncogene; 1997 Sep; 15(11):1303-7. PubMed ID: 9315098
[TBL] [Abstract][Full Text] [Related]
26. Cyclin-dependent kinase 7 inhibitors in cancer therapy.
Wang M; Wang T; Zhang X; Wu X; Jiang S
Future Med Chem; 2020 May; 12(9):813-833. PubMed ID: 32208930
[TBL] [Abstract][Full Text] [Related]
27. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists.
Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y
Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587
[TBL] [Abstract][Full Text] [Related]
28. Active growth signaling promotes senescence and cancer cell sensitivity to CDK7 inhibition.
Wilson GA; Vuina K; Sava G; Huard C; Meneguello L; Coulombe-Huntington J; Bertomeu T; Maizels RJ; Lauring J; Kriston-Vizi J; Tyers M; Ali S; Bertoli C; de Bruin RAM
Mol Cell; 2023 Nov; 83(22):4078-4092.e6. PubMed ID: 37977119
[TBL] [Abstract][Full Text] [Related]
29. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma.
García-Reyes B; Kretz AL; Ruff JP; von Karstedt S; Hillenbrand A; Knippschild U; Henne-Bruns D; Lemke J
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340359
[TBL] [Abstract][Full Text] [Related]
30. Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells.
Yu J; Guo QL; You QD; Zhao L; Gu HY; Yang Y; Zhang HW; Tan Z; Wang X
Carcinogenesis; 2007 Mar; 28(3):632-8. PubMed ID: 17012222
[TBL] [Abstract][Full Text] [Related]
31. Discovery of SHR5428 as a selective and noncovalent inhibitor of CDK7.
Jia M; Wang W; Chen G; Wu T; Zhang T; Zhou Q; Yin J; Li J; Li X; Mao Y; Feng J; Hu M; Li X; He F
Bioorg Med Chem Lett; 2023 Sep; 93():129429. PubMed ID: 37543274
[TBL] [Abstract][Full Text] [Related]
32. Cdc25 phosphatases are required for timely assembly of CDK1-cyclin B at the G2/M transition.
Timofeev O; Cizmecioglu O; Settele F; Kempf T; Hoffmann I
J Biol Chem; 2010 May; 285(22):16978-90. PubMed ID: 20360007
[TBL] [Abstract][Full Text] [Related]
33. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer.
Wang BY; Liu QY; Cao J; Chen JW; Liu ZS
Drug Des Devel Ther; 2016; 10():1181-9. PubMed ID: 27042010
[TBL] [Abstract][Full Text] [Related]
34. Structural basis for CDK7 activation by MAT1 and Cyclin H.
Peissert S; Schlosser A; Kendel R; Kuper J; Kisker C
Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26739-26748. PubMed ID: 33055219
[TBL] [Abstract][Full Text] [Related]
35. CDK7 inhibitors as anticancer drugs.
Sava GP; Fan H; Coombes RC; Buluwela L; Ali S
Cancer Metastasis Rev; 2020 Sep; 39(3):805-823. PubMed ID: 32385714
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome.
Kapasi AJ; Spector DH
J Virol; 2008 Jan; 82(1):394-407. PubMed ID: 17942543
[TBL] [Abstract][Full Text] [Related]
37. Cyclin-dependent kinase-2 (Cdk2) forms an inactive complex with cyclin D1 since Cdk2 associated with cyclin D1 is not phosphorylated by Cdk7-cyclin-H.
Higashi H; Suzuki-Takahashi I; Saitoh S; Segawa K; Taya Y; Okuyama A; Nishimura S; Kitagawa M
Eur J Biochem; 1996 Apr; 237(2):460-7. PubMed ID: 8647086
[TBL] [Abstract][Full Text] [Related]
38. Targeting Super-Enhancer-Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor.
Zhang J; Liu W; Zou C; Zhao Z; Lai Y; Shi Z; Xie X; Huang G; Wang Y; Zhang X; Fan Z; Su Q; Yin J; Shen J
Clin Cancer Res; 2020 Jun; 26(11):2681-2692. PubMed ID: 31937612
[TBL] [Abstract][Full Text] [Related]
39. Regulation of CDK7-carboxyl-terminal domain kinase activity by the tumor suppressor p16(INK4A) contributes to cell cycle regulation.
Nishiwaki E; Turner SL; Harju S; Miyazaki S; Kashiwagi M; Koh J; Serizawa H
Mol Cell Biol; 2000 Oct; 20(20):7726-34. PubMed ID: 11003668
[TBL] [Abstract][Full Text] [Related]
40. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]